Association between the apoptotic effect of Cabazitaxel and its pro-oxidant efficacy on the redox adaptation mechanisms in prostate cancer cells with different resistance phenotypes

References

• Hayes JD, Dinkova-Kostova AT, Tew KD. Oxidative stress in cancer. Cancer Cell. 2020;38(2):167–12. doi:10.1016/j.ccell.2020.06.001.
   PubMed Web of Science ®Google Scholar
• Hegedűs C, Kovács K, Polgár Z, Regdon Z, Szabó É, Robaszkiewicz A, Forman HJ, Martner A, Virág L. Redox control of cancer cell destruction. Redox Biol. 2018;16:59–74. doi:10.1016/j.redox.2018.01.015.
   PubMed Web of Science ®Google Scholar
• Moloney JN, Cotter TG. ROS signaling in the biology of cancer. Semin Cell Dev Biol. 2018;80:50–64. doi:10.1016/j.semcdb.2017.05.023.
   PubMed Web of Science ®Google Scholar
• Liu Y, Li Q, Zhou L, Xie N, Nice EC, Zhang H, Huang C, Lei Y. Cancer drug resistance: redox resetting renders a way. Oncotarget. 2016;7(27):42740–42761. doi:10.18632/oncotarget.8600.
   PubMedGoogle Scholar
• Firczuk M, Bajor M, Graczyk-Jarzynka A, Fidyt K, Goral A, Zagozdzon R. Harnessing altered oxidative metabolism in cancer by augmented prooxidant therapy. Cancer Lett. 2020;471:1–11. doi:10.1016/j.canlet.2019.11.037.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48. doi:10.3322/caac.21763.
   PubMed Web of Science ®Google Scholar
• Corn PG, Agarwal N, Araujo JC, Sonpavde G. Taxane-based combination therapies for metastatic prostate cancer. Eur Urol Focus. 2019;5(3):369–380. doi:10.1016/j.euf.2017.11.009.
   PubMedGoogle Scholar
• Duran GE, Wang YC, Francisco EB, Rose JC, Martinez FJ, Coller J, Brassard D, Vrignaud P, Sikic BI. Mechanisms of resistance to cabazitaxel. Mol Cancer Ther. 2015;14(1):193–201. doi:10.1158/1535-7163.MCT-14-0155.
   PubMed Web of Science ®Google Scholar
• Galletti G, Leach BI, Lam L, Tagawa ST. Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer. Cancer Treat Rev. 2017;57:16–27. doi:10.1016/j.ctrv.2017.04.008.
   PubMed Web of Science ®Google Scholar
• Cui Q, Wang JQ, Assaraf YG, Ren L, Gupta P, Wei L, Jr Ashby CR, Yang DH, Chen ZS. Modulating ROS to overcome multidrug resistance in cancer. Drug Resist Updat. 2018;41:1–25. doi:10.1016/j.drup.2018.11.001.
   PubMed Web of Science ®Google Scholar
• Xue D, Zhou X, Qiu J. Emerging role of NRF2 in ROS-mediated tumor chemoresistance. Biomed Pharmacother. 2020;131:110676. doi:10.1016/j.biopha.2020.110676.
   PubMed Web of Science ®Google Scholar
• Eryilmaz IE, Egeli U, Cecener G. An in vitro redox adaptation model for metastatic prostate cancer: Establishing, characterizing and Cabazitaxel response evaluating. Clin Exp Pharmacol Physiol. 2022;49(10):1094–1104. doi:10.1111/1440-1681.13694.
   PubMed Web of Science ®Google Scholar
• Ramanathan B, Jan KY, Chen CH, Hour TC, Yu HJ, Pu YS. Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Res. 2005;65:8455–8460. doi:10.1158/0008-5472.CAN-05-1162.
   PubMed Web of Science ®Google Scholar
• Mizumachi T, Suzuki S, Naito A, Carcel-Trullols J, Evans TT, Spring PM, Oridate N, Furuta Y, Fukuda S, Higuchi M. Increased mitochondrial DNA induces acquired docetaxel resistance in head and neck cancer cells. Oncogene. 2008;27(6):831–838. doi:10.1038/sj.onc.1210681.
   PubMed Web of Science ®Google Scholar
• Kosaka T, Hongo H, Miyazaki Y, Nishimoto K, Miyajima A, Oya M. Reactive oxygen species induction by cabazitaxel through inhibiting sestrin-3 in castration resistant prostate cancer. Oncotarget. 2017;8(50):87675–87683. doi:10.18632/oncotarget.21147.
   PubMedGoogle Scholar
• Kumar B, Koul S, Khandrika L, Meacham RB, Koul HK. Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res. 2008;68:1777–1785. doi:10.1158/0008-5472.CAN-07-5259.
   PubMed Web of Science ®Google Scholar
• Espinosa-Diez C, Miguel V, Mennerich D, Kietzmann T, Sánchez-Pérez P, Cadenas S, Lamas S. Antioxidant responses and cellular adjustments to oxidative stress. Redox Biol. 2015;6:183–197. doi:10.1016/j.redox.2015.07.008.
   PubMed Web of Science ®Google Scholar
• Chaiswing L, St Clair WH, St Clair DK. Redox Paradox: a novel approach to therapeutics-resistant cancer. Antioxid Redox Signal. 2018;29(13):1237–1272. doi:10.1089/ars.2017.7485.
   PubMed Web of Science ®Google Scholar
• Tonelli C, Chio IIC, Tuveson DA. Transcriptional regulation by Nrf2. Antioxid Redox Signal. 2018;29(17):1727–1745. doi:10.1089/ars.2017.7342.
   PubMed Web of Science ®Google Scholar
• Görlach A. Regulation of HIF-1α at the transcriptional level. CPD. 2009;15(33):3844–3852. doi:10.2174/138161209789649420.
   Google Scholar
• Wu S, Lu H, Bai Y. Nrf2 in cancers: a double-edged sword. Cancer Med. 2019;8(5):2252–2267. doi:10.1002/cam4.2101.
   PubMed Web of Science ®Google Scholar
• Sennoune SR, Nelius T, Jarvis C, Pruitt K, Kottapalli KR, Filleur S. The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells. PLoS One. 2020;15(6):e0234078. doi:10.1371/journal.pone.0234078.
   PubMed Web of Science ®Google Scholar
• Li Z, Xuan Z, Chen J, Song W, Zhang S, Jin C, Zhou M, Zheng S, Song P. Inhibiting the NF-κB pathway enhances the antitumor effect of cabazitaxel by downregulating bcl-2 in pancreatic cancer. Int J Oncol. 2020;57(1):161–170. doi:10.3892/ijo.2020.5053.
   PubMed Web of Science ®Google Scholar
• Guney Eskiler G, Ozkan AD, Eryilmaz IE, Egeli U, Cecener G. Association between the anticancer efficacy of cabazitaxel and toll-like receptor 4 mediating signaling pathways in metastatic castration-resistant prostate cancer cells. Hum Exp Toxicol. 2021;40(7):1122–1129. doi:10.1177/0960327120984209.
   PubMed Web of Science ®Google Scholar
• Ríos-Colón L, Cajigas-Du Ross CK, Basu A, Elix C, Alicea-Polanco I, Sanchez TW, Radhakrishnan V, Chen CS, Casiano CA. Targeting the stress oncoprotein LEDGF/p75 to sensitize chemoresistant prostate cancer cells to taxanes. Oncotarget. 2017;8(15):24915–24931. doi:10.18632/oncotarget.15323.
   PubMedGoogle Scholar